Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: Understanding the immune response in very mild and asymptomatic COVID-19 is crucial for developing effective vaccines and immunotherapies, yet remains poorly characterized. This longitudinal study examined the evolution of interferon (IFN)-γ responses to SARS-CoV-2 peptides in 109 asymptomatic or mildly symptomatic Ugandan COVID-19 patients across 365 days and explored their association with antibody generation.
METHODS: T-cell responses to spike-containing clusters of differentiation (CD4)-S and CD8 nCoV-A (CD8-A) megapools, and the non-spike CD4-R and CD8 nCoV-B (CD8-B) megapools, were assessed and correlated with demographic and temporal variables.
RESULTS: SARS-CoV-2-specific IFN-γ responses were consistently detected in all peptide pools and time points, with the spike-targeted response exhibiting higher potency and durability than the non-spike responses. Throughout the entire 365-day infection timeline, a robust positive correlation was observed between CD4 T-cell responses to the spike-derived peptides and anti-spike immunoglobulin G antibody levels, underscoring their interdependent dynamics in the immune response against SARS-CoV-2; in contrast, CD8 T-cell responses exhibited no such correlation, highlighting their distinctive, autonomous role in defense. No meaningful variations in complete blood count parameters were observed between individuals with COVID-19 infection and those without, indicating clinical insignificance.
CONCLUSIONS: This study highlights the dominant role of spike-directed T-cell responses in mild and asymptomatic disease and provides crucial longitudinal data from Sub-Saharan African settings. The findings provide valuable insights into the dynamics of T-cell responses and their potential significance in developing effective strategies for combating COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:136 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 136(2023) vom: 20. Nov., Seite 49-56 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ssali, Ivan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2023.09.001 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361812442 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361812442 | ||
| 003 | DE-627 | ||
| 005 | 20240214232805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.09.001 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM361812442 | ||
| 035 | |a (NLM)37683720 | ||
| 035 | |a (PII)S1201-9712(23)00714-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ssali, Ivan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: Understanding the immune response in very mild and asymptomatic COVID-19 is crucial for developing effective vaccines and immunotherapies, yet remains poorly characterized. This longitudinal study examined the evolution of interferon (IFN)-γ responses to SARS-CoV-2 peptides in 109 asymptomatic or mildly symptomatic Ugandan COVID-19 patients across 365 days and explored their association with antibody generation | ||
| 520 | |a METHODS: T-cell responses to spike-containing clusters of differentiation (CD4)-S and CD8 nCoV-A (CD8-A) megapools, and the non-spike CD4-R and CD8 nCoV-B (CD8-B) megapools, were assessed and correlated with demographic and temporal variables | ||
| 520 | |a RESULTS: SARS-CoV-2-specific IFN-γ responses were consistently detected in all peptide pools and time points, with the spike-targeted response exhibiting higher potency and durability than the non-spike responses. Throughout the entire 365-day infection timeline, a robust positive correlation was observed between CD4 T-cell responses to the spike-derived peptides and anti-spike immunoglobulin G antibody levels, underscoring their interdependent dynamics in the immune response against SARS-CoV-2; in contrast, CD8 T-cell responses exhibited no such correlation, highlighting their distinctive, autonomous role in defense. No meaningful variations in complete blood count parameters were observed between individuals with COVID-19 infection and those without, indicating clinical insignificance | ||
| 520 | |a CONCLUSIONS: This study highlights the dominant role of spike-directed T-cell responses in mild and asymptomatic disease and provides crucial longitudinal data from Sub-Saharan African settings. The findings provide valuable insights into the dynamics of T-cell responses and their potential significance in developing effective strategies for combating COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Hematological parameters | |
| 650 | 4 | |a IFN-γ | |
| 650 | 4 | |a Immunodominance | |
| 650 | 4 | |a Long-term immunity | |
| 650 | 4 | |a Mild and asymptomatic COVID-19 | |
| 650 | 4 | |a Spike protein | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Mugaba, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Watelo, Arthur Kalyebi |e verfasserin |4 aut | |
| 700 | 1 | |a Bemanzi, Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Katende, Joseph Ssebwana |e verfasserin |4 aut | |
| 700 | 1 | |a Oluka, Gerald Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Ankunda, Violet |e verfasserin |4 aut | |
| 700 | 1 | |a Baine, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Laban |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Immunoprofiling Team |e verfasserin |4 aut | |
| 700 | 1 | |a Onyachi, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Muwanga, Moses |e verfasserin |4 aut | |
| 700 | 1 | |a Jjuuko, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Kayiwa, John |e verfasserin |4 aut | |
| 700 | 1 | |a Nsereko, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Auma, Betty Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Weiskopf, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Sette, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Lutalo, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Musenero, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Kaleebu, Pontiano |e verfasserin |4 aut | |
| 700 | 1 | |a Serwanga, Jennifer |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 136(2023) vom: 20. Nov., Seite 49-56 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:136 |g year:2023 |g day:20 |g month:11 |g pages:49-56 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2023.09.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 136 |j 2023 |b 20 |c 11 |h 49-56 | ||